http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Woon Geon Sh (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Na Seunghee,Kang Dong Woo,Kim Geon Ha,Kim Ko Woon,Kim Yeshin,Kim Hee-Jin,Park Kee Hyung,Park Young Ho,Byeon Gihwan,Suh Jeewon,Shin Joon Hyun,Shim YongSoo,Yang YoungSoon,Um Yoo Hyun,Oh Seong-il,Wang Sh 대한치매학회 2024 Dementia and Neurocognitive Disorders Vol.23 No.1
Background and Purpose: Dementia subtypes, including Alzheimer’s dementia (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), pose diagnostic challenges. This review examines the effectiveness of 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) in differentiating these subtypes for precise treatment and management. Methods: A systematic review following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines was conducted using databases like PubMed and Embase to identify studies on the diagnostic utility of 18F-FDG PET in dementia. The search included studies up to November 16, 2022, focusing on peer-reviewed journals and applying the gold-standard clinical diagnosis for dementia subtypes. Results: From 12,815 articles, 14 were selected for final analysis. For AD versus FTD, the sensitivity was 0.96 (95% confidence interval [CI], 0.88–0.98) and specificity was 0.84 (95% CI, 0.70–0.92). In the case of AD versus DLB, 18F-FDG PET showed a sensitivity of 0.93 (95% CI 0.88-0.98) and specificity of 0.92 (95% CI, 0.70–0.92). Lastly, when differentiating AD from non-AD dementias, the sensitivity was 0.86 (95% CI, 0.80–0.91) and the specificity was 0.88 (95% CI, 0.80–0.91). The studies mostly used case-control designs with visual and quantitative assessments. Conclusions: 18F-FDG PET exhibits high sensitivity and specificity in differentiating dementia subtypes, particularly AD, FTD, and DLB. This method, while not a standalone diagnostic tool, significantly enhances diagnostic accuracy in uncertain cases, complementing clinical assessments and structural imaging.
-
( Joo Hyun Lim ),( Sang Gyun Kim ),( Ji Hyun Song ),( Jae Jin Hwang ),( Dong Ho Lee ),( Jae Pil Han ),( Su Jin Hong ),( Ji Hyun Kim ),( Seong Woo Jeon ),( Gwang Ha Kim ),( Ki-Nam Shim ),( Woon Geon Sh 대한소화기학회 2017 Gut and Liver Vol.11 No.2
Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the ef-ficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regi-mens and durations, and types of peptic ulcers were ana-lyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithro-mycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duode-nal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed ef-ficacy similar to that of previously reported first/second-line therapies. (Gut Liver 2017;11:226-231)
ScienceON
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
